Molbio Diagnostics IPO

Molbio Diagnostics follows a razor-and-blade model, where selling a testing device leads to regular sales of disposable test kits. In FY26, test kit sales contributed ₹1,034.82 crore, accounting for 73.98% of its total operating revenue of ₹1,445.69 crore. This gives the company a steady and predictable source of recurring income.

The company has delivered healthy financial growth over the past few years. Its revenue from operations increased from ₹836.56 crore in FY24 to ₹1,445.69 crore in FY26. During the same period, its restated profit (profit adjusted to make past financials comparable) nearly doubled to ₹164.14 crore.

Molbio operates in an oligopolistic market (a market dominated by only a few players), where it is difficult for new companies to enter because of the high cost and time needed for research. Its Truenat platform took 13 years of R&D to receive ICMR certification and remains the only Indian-made rapid molecular test approved by the WHO for initial Tuberculosis diagnosis.

The company continues to expand its range of diagnostic tests by investing heavily in research. In FY26, it spent ₹87.46 crore, or 6.05% of its operating revenue, on R&D. It also has a dedicated R&D team of 153 permanent employees, including 136 scientists, helping it stay ahead in product development.

Molbio has maintained healthy profitability while using its capital efficiently. In FY26, its Return on Equity (ROE) - a measure of how efficiently it generates profit from shareholders' money - stood at 15.59%, while its Return on Capital Employed (ROCE) - which shows how efficiently the business uses all its capital - was 17.55%.

The company has steadily expanded the number of diseases its platform can detect. Its commercialized portfolio grew from 26 diseases and 38 assays (individual diagnostic tests) in FY24 to 30 diseases and 43 assays in FY26. This makes its Truenat platform useful for a wider range of medical conditions over time.

Molbio is led by professionals with decades of experience in the diagnostics industry. CEO Sriram Natarajan co-founded Tulip Diagnostics in 1990 and brings 35 years of industry experience. Chief Technical Officer Dr. Chandrasekhar Nair has 34 years of research expertise, which has played an important role in developing and scaling the company's products.

Molbio Diagnostics depends heavily on government healthcare programs. In FY26, sales to Indian government bodies and international aid agencies accounted for 84.56% of its finished goods sales. The concentration is even higher among its largest customers, with the top 10 contributing 83.26% of sales. Its biggest customer alone accounted for 56.52%, or ₹790.65 crore. Losing a major customer or a large government contract could significantly affect its revenue.

The company also has a high dependence on one product segment. Tuberculosis (TB) diagnostic tests contributed 70.20% of its finished goods revenue in FY26, generating ₹982.01 crore. If global funding for TB programs declines or demand for TB testing falls, the company's financial performance could be affected.

Because a large part of its business comes from government customers, payments often take longer to arrive. As a result, the company had 166 working capital days (the time cash remains tied up in the business) in FY26 and an average credit period of 86 days. Its outstanding trade receivables (money yet to be collected from customers) stood at ₹408.74 crore, which could put pressure on its day-to-day cash flow.

The company has significantly increased its borrowings to fund acquisitions and meet working capital needs. As of May 31, 2026, its consolidated outstanding debt stood at ₹422.50 crore. Higher debt also means higher interest and repayment obligations, which could reduce the cash available for future expansion or research.

Molbio imported 42.01% of its raw materials in FY26, worth ₹243.40 crore. Since it does not have a formal hedging policy (a strategy to reduce the impact of currency movements), fluctuations in foreign exchange rates can affect its costs. In FY26, the company reported a foreign exchange loss of ₹7.24 crore.

Some of the company's acquisitions are still reporting losses, which has affected its overall profitability. In FY26, OptraScan INC reported a loss of ₹11.14 crore, while Prognosys Healthcare (India) Private Limited posted a loss of ₹0.70 crore. If these businesses continue to underperform, they could remain a drag on the company's financial performance.

The company takes a relatively long time to convert its inventory into sales. Its inventory turnover ratio improved slightly from 1.03 times in FY24 to 1.30 times in FY26 but remained low. As of March 31, 2026, inventory worth ₹449.26 crore was tied up in stock, locking a significant amount of capital.